10 Best Under-the-Radar Stocks to Invest In
In this article, we will discuss: 10 Best Under-the-Radar Stocks to Invest In.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Baker Bros. Advisors Julian Baker And Felix Baker | 2,143,131 | $1,150,754,190 | +1% | 5.77% |
| 2. | VenBio Select Advisor Kurt Von Emster | 1,833,333 | $984,408,154 | +1% | 8.84% |
| 3. | Paulson & Co John Paulson | 1,340,020 | $719,523,739 | -4% | 27.94% |
| 4. | Citadel Investment Group Ken Griffin | 507,233 | $272,358,759 | +12% | 0.03% |
| 5. | Armistice Capital Steven Boyd | 288,000 | $154,641,600 | +9% | 1.89% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $392.24 | 9,362 | $3,672,178.03 | 1,947,968 | 2025-08-20 | Filing | |
| $392.24 | 862 | $338,113.38 | 202,813 | 2025-08-20 | Filing | |
| $389.89 | 2,506 | $977,058.83 | 1,938,606 | 2025-08-20 | Filing | |
| $389.89 | 231 | $90,064.08 | 201,951 | 2025-08-20 | Filing | |
| $389.00 | 366 | $142,374.00 | 1,936,100 | 2025-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $546.38 | 120 | $65,565.20 | 197,746 | 2026-09-11 | Filing | |
| $544.83 | 761 | $414,616.16 | 197,866 | 2026-09-11 | Filing | |
| $544.02 | 1,539 | $837,252.94 | 198,627 | 2026-09-11 | Filing | |
| $542.60 | 1,202 | $652,209.05 | 200,166 | 2026-09-11 | Filing | |
| $541.64 | 368 | $199,324.37 | 201,368 | 2026-09-11 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3 | $1,512 | 0% | |
| 2. | 2 | $1 | 0% |
News See All
12 Best High Short Interest Stocks With Highest Upside Potential
In this article, we will discuss the 12 Best High Short Interest Stocks With Highest Upside Potential.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2026 Earnings Call Transcript May 6, 2026Madrigal Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-3.25, expectations were $-3.61.
Madrigal Pharmaceuticals (MDGL) Surged on Strong Sales of Its Rezdiffra Drug
Janus Henderson Investors, an investment management company, released its “Forty Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S.
What Makes Madrigal Pharma (MDGL) One of the Shorted Biotech Stocks to Buy
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the 10 most shorted biotech stocks to buy according to hedge funds.
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds
On February 5, J.P. Morgan shared its views on trends that are expected to define healthcare in 2026.
Madrigal Pharmaceuticals (MDGL) Reports Record 2025 Revenue Driven by Rezdiffra Success
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the stocks with explosive growth potential.
10 Stocks With Explosive Growth Potential
On February 26, Darren Sissons, partner and portfolio manager at Campbell, Lee & Ross Investment Management, appeared on BNN Bloomberg to share his outlook on Global and Technology Stocks.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2025 Earnings Call Transcript February 19, 2026Madrigal Pharmaceuticals, Inc. misses on earnings expectations.
H.C. Wainwright Keeps Buy on Madrigal Pharmaceuticals (MDGL) on Strong Rezdiffra Uptake and F2/F3 MASH Patient Data
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the high short interest stocks to buy right now. On November 21, H.C.
Hedge Fund Resource Center